Ruboxistaurin results: Eli Lilly plans more trials


Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.